Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrara

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
Frontiers in Oncology|February 9, 2023
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.
Cancer Treatment and Research Communications|February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational studyPaolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Cancer Treatment and Research Communications|March 9, 2026
A viable human lung cancer tissue collection (LCTC) to accelerate translational researchVirginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, et al.
Clinical Lung Cancer|January 23, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchArsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
Frontiers in Oncology|February 9, 2023
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.
Cancer Treatment and Research Communications|February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational studyPaolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Cancer Treatment and Research Communications|March 9, 2026
A viable human lung cancer tissue collection (LCTC) to accelerate translational researchVirginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, et al.
Clinical Lung Cancer|January 23, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchArsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 15